Survival After Cancer in Italian Persons With AIDS, 1986–2005
Authors:
- Luigino Dal MasoLMLuigino Dal Maso
- Barbara SuligoiBSBarbara Suligoi
- Silvia FranceschiSFSilvia Franceschi
- Claudia BragaCBClaudia Braga
- Carlotta BuzzoniCBCarlotta Buzzoni
- Jerry PoleselJerry Polesel
- Antonella ZucchettoAZAntonella Zucchetto
- Pierluca PiselliPPPierluca Piselli
- Fabio FalciniFFFabio Falcini
- Adele CaldarellaACAdele Caldarella
- Roberto ZanettiRZRoberto Zanetti
- Marina VercelliMVMarina Vercelli
- 1 August 2014
- journal article
- review article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 66 (4) , 428-435
Abstract
Background: Cancer survival in persons with AIDS (PWA) after introduction of antiretroviral therapies remains poorly characterized. The aim is to provide population-based estimates of cancer survival, overall and for the most important cancer types in PWA, and a comparison with persons without AIDS (non-PWA) affected by the same cancer. Methods: PWA with cancer at AIDS diagnosis or thereafter were individually matched with non-PWA by type of cancer, sex, age, year of diagnosis, area of living, and, for lymphomas, histological subtype. Five-year observed survival and hazard ratios (HRs) of death in PWA versus non-PWA with 95% confidence intervals (CIs) were estimated. Results: We included 2262 Italian PWA and 4602 non-PWA with cancer diagnosed during 1986–2005. Between 1986 and 1995, and 1996 and 2005, 5-year survival for all cancers in PWA improved from 12% to 41% and the corresponding HR versus non-PWA decreased from 5.1 (95% CI: 4.3 to 6.1) to 2.9 (95% CI: 2.6 to 3.3). During 1996–2005, HRs were 2.0 (95% CI: 1.4 to 2.9) for Kaposi sarcoma, 3.4 (95% CI: 2.9 to 4.1) for non-Hodgkin lymphoma, and 2.4 (95% CI: 1.4 to 4.0) for cervical cancer. HRs were 2.5 (95% CI: 2.1 to 3.1) for all non–AIDS-defining cancers, 5.9 (95% CI: 3.1 to 11.2) for Hodgkin lymphoma, and 7.3 (95% CI: 2.8 to 19.2) for nonmelanoma skin cancer. A ≤3-fold survival difference was found for cancers of the stomach, liver, anus, lung, brain, and the most aggressive lymphoma subtypes. Conclusions: The persisting, although narrowing, gap in cancer survival between PWA and non-PWA indicates the necessity of enhancing therapeutic approaches, so that PWA can be provided the same chances of survival observed in the general population, and improving cancer prevention and screening.Keywords
This publication has 41 references indexed in Scilit:
- Causes of death among Danish HIV patients compared with population controls in the period 1995–2008Infection, 2012
- Cancer as a Cause of Death among People with AIDS in the United StatesClinical Infectious Diseases, 2010
- The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies eraCancer Epidemiology, 2010
- Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D studyAIDS, 2010
- Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort StudiesClinical Infectious Diseases, 2010
- Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data From 25 States, United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Survival After AIDS Diagnosis in Italy, 1999-2006: A Population-Based StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapyAIDS, 2009
- Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General PopulationJAMA, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008